Poly(hydroxy-oxazolidone) Thermoplastic Elastomers for Safer and 3D Printable Blood-Contacting Medical Devices



<u>Anna Pierrard</u>¹, Sofia Melo², Marco Caliari^{1,3}, Haritz Sardon³, Patrizio Lancellotti^{2,4}, Christophe Detrembleur¹, Cecile Oury², Christine Jérôme¹



¹Center for Education and Research on Macromolecules, ULiège, Liège (Belgium)

²GIGA Metabolism & Cardiovascular Biology - Laboratory of Cardiology, ULiège, Liège (Belgium)


³POLYMAT and Department of Polymers and Avanced Materials: Physics, Chemistry and Technology, University of the Basque Country UPV/EHU, Donostia-San Sebastian (Spain)

⁴Heart Valve Clinic, University Hospital Center (CHU) of Liège, Liège (Belgium)



INTRODUCTION

Polyurethanes are among the most produced families of polymer in the world and are used in many applications, including in the biomedical field, such as in catheters, cardiac-assist devices and various implants. Unfortunately, they are produced from highly toxic reagents (isocyanates), responsible for environmental and health issues. The aim of this work was therefore to develop a **new alternative biomaterial** by using a **greener and safer synthetic route**. A poly(hydroxy-oxazolidone) (**PHOx**), containing cyclic urethane linkages, exhibiting remarkable thermoplastic elastomer properties and **suitable** for various processing technologies, including **3D-printing** and **electrospinning** was thereby obtained by reaction between precisely chosen **CO₂-sourced** cyclic carbonate and diamine monomers.



This new, safer and greener biomaterial has better biological performance than medical-grade polyurethane!

CONCLUSION

- The analysis of the physicochemical properties and the *in vitro* and *in vivo* compatibility studies performed on this new highly promising biomaterial prove its suitability for use in biomedical applications (e.g., cardiovascular implants/devices).
- Its thermoplastic behavior allows its easy processing by various thermal-based techniques, including 3D-printing, which also shows the future possibility of customizing parts for personalized devices/implants.

ACKNOWLEDGEMENTS

The authors thank the F.R.S.-FNRS (for the FRIA grant of S.F.M, the Research Director positions of C.D. and C.O.), the CO_2 Switch project (convention T.0075.20), as well as the Fondation Léon Fredericq.

REFERENCES

Naficy S. et al. *Materials Today Communications*, **2022**, 33, 104916. Detrembleur C. et al. *Macromolecules*, **2020**, 53, 15, 6396-6408. Patent WO 2025/082761, **2025**.

Paper accepted in *Adv. Healthc. Mater.* **2025.**